Drug Trial Radar · NCT07559929
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Aug 19, 2026
Primary completion
Jun 1, 2028
Study completion Dec 30, 2030
Sponsor
- Lead sponsor
- Hangzhou DAC Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006 in combination with an immune checkpoint inhibitor (ICI) or platinum-based chemotherapy in patients with small cell lung cancer (SCLC).
Conditions
- Small Cell Lung Cancer
Interventions
DXC006Drug
Participants receive DXC006 intravenously on Day 1 every 3 weeks.
ToripalimabDrug
Participants receive Toripalimab intravenously on Day 1 every 3 weeks.
CarboplatinDrug
Participants receive Carboplatin intravenously on Day 1 every 3 weeks (up to 6 cycles).
CisplatinDrug
Participants receive Cisplatin intravenously on Day 1 every 3 weeks (up to 6 cycles).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 year.
- 6-month progression-free survival rateTime frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.
- Recommended Phase 2 Dose (RP2D)Time frame: Final RP2D confirmation upon completion of the Phase Ib (up to 12 months).
- Measurement of objective response rate (ORR) per RECIST 1.1Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 year.
- Measurement of disease control rate (DCR)Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 year.
- Incidence of Adverse Events (AEs)Time frame: After first infusion of study drug, through study completion an average of 2 year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.